Society Logo
ME/CFS Australia Ltd
Please Click Here To Donate ME/CFS Australia (SA) Inc
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 277KB)
Why become a member?

Study provides evidence of milnacipran efficacy for the long-term treatment of Fibromyalgia

Monday 5 March 2012

 

From MPR:

 

MPRStudy Provides Evidence of Milnacipran Efficacy for the Long-Term Treatment of Fibromyalgia


February 27 2012

PALM SPRINGS, CA — A study that evaluated the effect of discontinuing long-term treatment with milnacipran on the symptoms of fibromyalgia found that once the agent was withdrawn, time to loss of therapeutic response was significantly shorter than in patients who continued treatment, investigators reported during the 2012 American Academy of Pain Medicine Annual Meeting.

The multicenter, double-blind, placebo-controlled discontinuation study included 150 patients with fibromyalgia who were enrolled for up to 3.25 years (minimum, 17.9 months) in an open-label study of milnacipran, noted Daniel J. Clauw, MD, of the University of Michigan, Ann Arbor, MI, and colleagues.

The patients entered the study directly from a three-year, open-label, flexible-dose follow-up study and continued their previous milnacipran 50–200mg/day dosage for an additional four weeks of open-label treatment. Responders — those on a ≥100mg/day dose who had achieved a ≥50% reduction in pain compared to before milnacipran exposure on a visual analog scale (VAS) — were randomized 2:1 to milnacipran (milnacipran continued; n=100) or placebo (milnacipran withdrawn; n=50) for 12 weeks.

The patient population was predominantly female (96%) and white (95%). Mean VAS pain score at the baseline randomization visit was 17.5, which represented a 73% reduction from the pretreatment baseline mean score of 65.7.

Time to loss of therapeutic response was the primary efficacy parameter, defined as an increase in VAS pain score to <30% reduction from pre-milnacipran exposure or a fibromyalgia that worsened, requiring an alternative treatment.

At 12 weeks, 64% of patients withdrawn from milnacipran met the criteria for loss of therapeutic response compared with 35% of patients who had continued milnacipran. Median time to loss of therapeutic response was 56 days for patients withdrawn from milnacipran and not calculable for those who continued the agent (P=0.0004).

“In patients who have received long-term treatment with milnacipran (1.5 to 4.5 years), the loss of therapeutic response upon discontinuation of treatment provides evidence of long-term efficacy of milnacipran as a treatment for fibromyalgia,” Dr. Clauw and colleagues concluded. No new safety concerns were observed following milnacipran treatment discontinuation.

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus

Previous Previous Page